Cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors are a class of medications developed to address the underlying genetic defect responsible for cystic fibrosis (CF). CF is a genetic disorder that causes mucus to become thick and sticky, leading to severe respiratory and digestive problems. CFTR inhibitors aim to correct the malfunctioning CFTR protein, which regulates salt and water movement in and out of cells. By targeting CFTR, these drugs help improve chloride transport and reduce the severity of CF symptoms, ultimately enhancing the quality of life for individuals living with this challenging condition.
